organization · Reporting owner

KKR Biosimilar GP LLC

Disclosed activity across 1 company

Tapewire entity: 16476
SEC CIK: 0001624305

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Coherus Oncology, Inc.

Report date November 12, 2014 · Filed November 14, 2014

Jointly reported with KKR Biosimilar L.P., KKR Group Partnership L.P., KKR Fund Holdings GP Ltd, KKR Group Holdings L.P., KKR Group Ltd, KKR & Co. Inc., KKR Management LLP, KRAVIS HENRY R, ROBERTS GEORGE R

Section 16 reporting ended · disclosed 2014-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,499,499	Reported balance After 2014-11-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2014-11-12 · Conversion · Acquired 2,499,499 · Balance 2,499,499 F1: The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering. F2: Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2014-11-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2014-11-12 · Conversion · Disposed 2,499,499 · Balance 0 F1: The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering. F3: Not applicable. F2: Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering.

F2: Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC.

F3: Not applicable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 12, 2014 Filed Nov 14, 2014 21:29 UTC	Coherus Oncology, Inc. CHRS · Entity 6276	ConversionSeries C Preferred Stock · Derivative	2,499,499	$0.00	$0.00	Disclosure SEC source: 0001104659-14-080993 · a4.xml · derivative · entry 2 KKR Biosimilar L.P. · CIK 0001624314 · 10% owner KKR Biosimilar GP LLC · CIK 0001624305 · 10% owner KKR Fund Holdings L.P. · CIK 0001472698 · 10% owner KKR Fund Holdings GP Ltd · CIK 0001472697 · 10% owner KKR Group Holdings L.P. · CIK 0001472696 · 10% owner KKR Group Ltd · CIK 0001472695 · 10% owner KKR & Co. L.P. · CIK 0001404912 · 10% owner KKR Management LLC · CIK 0001472694 · 10% owner KRAVIS HENRY R · CIK 0001081714 · 10% owner ROBERTS GEORGE R · CIK 0001081715 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,499,499 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering. F1 · derivative.exercise_date: The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering. F3 · derivative.expiration_date: Not applicable. F2 · ownership.nature: Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC. Read SEC document
November 12, 2014 Filed Nov 14, 2014 21:29 UTC	Coherus Oncology, Inc. CHRS · Entity 6276	ConversionCommon Stock	2,499,499	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-14-080993 · a4.xml · nonDerivative · entry 1 KKR Biosimilar L.P. · CIK 0001624314 · 10% owner KKR Biosimilar GP LLC · CIK 0001624305 · 10% owner KKR Fund Holdings L.P. · CIK 0001472698 · 10% owner KKR Fund Holdings GP Ltd · CIK 0001472697 · 10% owner KKR Group Holdings L.P. · CIK 0001472696 · 10% owner KKR Group Ltd · CIK 0001472695 · 10% owner KKR & Co. L.P. · CIK 0001404912 · 10% owner KKR Management LLC · CIK 0001472694 · 10% owner KRAVIS HENRY R · CIK 0001081714 · 10% owner ROBERTS GEORGE R · CIK 0001081715 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,499,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Preferred Stock is convertible into shares of common stock of Coherus BioSciences, Inc. (the "Issuer") on a one-for-one basis and automatically converted into shares of common stock of the Issuer on a one-for-one basis immediately prior to the completion of Issuer's initial public offering. F2 · ownership.nature: Securities are held by KKR Biosimilar L.P. KKR Biosimilar GP LLC is the general partner of KKR Biosimilar L.P. KKR Fund Holdings L.P. is the sole member of KKR Biosimilar GP LLC. KKR Fund Holdings GP Limited is a general partner of KKR Fund Holdings L.P. KKR Group Holdings L.P. is the sole shareholder of KKR Fund Holdings GP Limited and a general partner of KKR Fund Holdings L.P. KKR Group Limited is the general partner of KKR Group Holdings L.P. KKR & Co. L.P. is the sole shareholder of KKR Group Limited. KKR Management LLC is the general partner of KKR & Co. L.P. Messrs. Henry R. Kravis and George R. Roberts are the designated members of KKR Management LLC. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.